Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00316511 | Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma | PHASE1 | COMPLETED | 21 | — | — | Mar 1, 2006 | - | Oct 27, 2008 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| Aroplatin | DRUG | - |
Inclusion Criteria: 1. Advanced solid malignancies or B-cell lymphoma 2. Less than or equal to 5 anti-cancer treatment regimens, which must be concluded at least four weeks prior to the first planned L-NDDP administration 3. Measurable disease 4. Eastern Cooperative Oncology Group (ECOG) performanc...